Bio-Bridge Science Signs Cooperative Agreement with Chinese Academy of Medical Sciences for Vaccine Development.

OAK BROOK, Ill. -- Bio-Bridge Science, Inc. (OTCBB: BGES) announced today that it has entered into a cooperative agreement with the Institute of Basic Medical Sciences at the Chinese Academy of Medical Sciences, a leading medical research institute in China, to research and develop a human papillomavirus polyvalent vaccine using prokaryotic expression system. This vaccine is designed to prevent from infection by human papillomavirus types 6, 11, 16, 18, 31, 45, and 58, which is expected to provide broader protection than the current vaccine in the market and have much lower production costs. Under the agreement, Bio-Bridge has been granted the preferential right to develop the vaccine and enjoys a 60% interest in the project.

Dr. Liang Qiao, Chairman and CEO of Bio-Bridge said, "We believe that our agreement with the Chinese Academy of Medical Sciences will enable us to solidify our research capability in China as we try to introduce more potential vaccine products in addition to our current vaccine pipeline. The Chinese Academy of Medical Sciences is a renowned medical research institute and is the national level medical science research center in China. We believe this cooperation will provide numerous benefits to both parties."

About Chinese Academy of Medical Sciences

The Chinese Academy of Medical Sciences was established in 1956 and is the national level medical science research center in China. Its former name was Peking Union Medical College, founded by the Rockefeller Foundation in 1917. The Academy has 49 doctorate disciplines and 52 master disciplines, 4 national level laboratories, 8 minister level laboratories and 6 post-doctor WHO research centers.

Forward Looking Statements:

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks defined in this document and in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof. Please refer to SEC filings for additional information.